41 results about "Stroke treatment" patented technology

The invention discloses a data mining and AI-based traditional Chinese medicine effective prescription screening and identifying method. The method comprises the following steps: S1, screening related literatures of traditional Chinese medicine prescriptions for stroke treatment in an academic journal database; s2, performing name standardization treatment on the traditional Chinese medicinal materials; s3, performing clustering analysis and correlation analysis on the traditional Chinese medicinal materials in the screened traditional Chinese medicinal prescription according to the monarch, minister, assistant and guide law in prescription compatibility; s4, screening core traditional Chinese medicinal materials, determining the correlation among the traditional Chinese medicinal materials in the law of monarch, minister, assistant and guide, and optimizing the compatibility rule to obtain a traditional Chinese medicine prescription for the optimal compatibility relationship of stroke treatment; the invention discovers the rule of treating stroke by traditional Chinese medicine, forms a paradigm method, optimizes the algorithm based on the theory of traditional Chinese medicine, reveals the compatibility rule of traditional Chinese medicinal materials in the traditional Chinese medicine prescription, screens core medicinal materials according to the monarch, minister, assistant and guide method, and obtains a specific paradigm of compatibility of seven traditional Chinese medicinal materials of angelica sinensis, lumbricus, ligusticum wallichii, peach kernel, astragalus membranaceus, safflower and red paeony root for stroke treatment.

The invention provides an in vitro method for determining the prognosis of a patient with stroke comprising: (i) determining, in a sample isolated from the patient, the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof, (ii) comparing the level of expression obtained in step (i) with a corresponding reference value, wherein if the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a bad prognosis. The invention also provides an in vitro method for deciding or recommending whether to initiate a medical regimen in a patient with stroke, and an in vitro method for determining the response of a patient already diagnosed with stroke, to a medical regimen for treating stroke. The invention further provides a miRNA inhibitor of a miRNA selected from the list consisting of miR-376c- 3p, miR-199a and combinations thereof, for use in the treatment or prevention of stroke in a patient. The invention also provides a combination of miRNAs comprising said miRNA inhibitor, and a pharmaceutical composition for use in the treatment or prevention of stroke.

The invention discloses a water-soluble bornyl ester compound and application thereof, the structure of the water-soluble bornyl ester compound is as shown in general formula I, R is acetic acid 2-oxoethyl ester of organic heterocyclic ring, amino acid 2-oxoethyl ester, glycolate of amino acid, acetal of monodisperse polyethylene glycol chain, carbonate, ester or glycosyl; the compound is good in water solubility, the problems that borneol is difficult to dissolve in water and difficult to prepare can be well solved, and in an inflammatory depression animal model, the bornyl ester compound shows good anti-inflammatory, anti-depression and cerebral apoplexy treatment effects and has great application prospects.

Clot engagement element comprising bundle of unwoven fibers can be assembled to form an acute stroke treatment device. The device has the capability of forming a three dimensional filtration matrix comprising effective pores with a distribution of sizes. The bundle of fiber design allows the device to be effectively delivered into circuitous cerebral arteries to remove clot that causes stroke. The fiber bundle based filtration matrix offers the advantages of conforming to the changing inner perimeter of a blood vessel during a clot removal process and thus the capability to effectively retain and remove a clot in the vessel. The filtration matrix offers the additional advantage to trap any break-off of the clot during the removal process. A plurality of fiber bundles can be combined to form an effective clot engagement element. Supplemental engagement structure as well as mechanical treatment structure can be integrated into the stroke treatment device. The deployment of the fiber based elements can be facilitated by actuation tool. Aspiration can be employed during the clot removal process.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The invention belongs to the technical field of heat stroke treatment, and particularly discloses an application of DNAzyme in preparation of a medicine for treating heat stroke, and the DNAzyme is the DNAzyme for targeted regulation and control of ZBP1 protein expression. The invention further discloses a medicine for preventing and treating heat stroke. The invention has an important value for a prevention and treatment method for fundamentally overcoming heat stroke. According to the application disclosed by the invention, the remarkable effect of the DNAzymeSEQ1 in prevention and treatment of the heat stroke is fully verified through a system experiment. The DNAzymeSEQ1 delivered by the TPNs carrier shows obvious liver and lung targeting in a mouse body, the fluorescence intensity is obviously higher than that of other organs, and it is ensured that the medicine accurately acts on a key injury part of heat stroke.

The present invention belongs to the field of biomedicine, discloses late endothelial progenitor cells and their application in the treatment of stroke, and also discloses biomarkers or methods for identifying or detecting early / late endothelial cells.

The invention discloses an implantable cerebral apoplexy treatment stimulator, which comprises at least two electrode parts and at least two skull nails, the at least two electrode parts are suitable for being respectively implanted into implantation holes of at least two skull, the electrode parts are connected with wires, the wires are connected with a pulse generator, each skull nail comprises a stud part and a screwing part, and the stud part is connected with the pulse generator. The stud part is suitable for being screwed into the implantation hole, the bottom of the stud part abuts against the top of the electrode part, the screwing part is connected to the top of the stud part, an operation groove is formed in the top of the screwing part, and a screw driver can be inserted into the operation groove to rotate the skull nail. The implantable cerebral apoplexy treatment stimulator is simpler in structure and more convenient to fix on the skull, the stimulation intensity can be improved, small-range lesions can be accurately targeted, stimulation is more accurate, in addition, stimulation parameters and stimulation areas can be adjusted and controlled, the implantable cerebral apoplexy treatment stimulator dynamically adapts to cerebral injury conditions of different patients, and the cerebral apoplexy treatment effect is better.

Methods and pharmaceutical compositions for treating stroke, intracranial hemorrhage and ischemic injury. The methods include administering a therapeutically effective amount of a matrix metalloproteinase 9 (MMP-9) antibody or antigen-binding fragment thereof that specifically binds MMP-9 and reduces MMP-9 activity, which treats stroke caused by intracranial hemorrhage and / or ischemic injury in a subject.

Disclosed is the compound of Formula (I), and pharmaceutical salts thereof, for use in the treatment of stroke (e.g. acute ischaemic stroke and haemorrhagic stroke) and post-stroke pain, wherein the compound is administered to a subject less than 6 hours from stroke onset. Also disclosed is the compound for use in preventing or reducing the risk of iatrogenic stroke and pharmaceutical compositions comprising the compound.

A computer-implemented method for predicting the outcome of an endovascular stroke treatment in a patient in need thereof before the endovascular treatment is performed in the patient. The method comprises the use of an apparatus characterised by comprising: a stimulator for providing electrical stimuli to one or more pairs of stimulating electrodes for stimulating a nerve; a voltmeter connected to one or more pairs of recording electrodes for recording a somatosensory evoked potential (SEP) resulting from the electrical stimuli provided to the nerve; and a processor.

The utility model relates to the technical field of fumigation equipment, and discloses fumigation equipment for stroke treatment in the internal medicine of traditional Chinese medicine, which comprises a shell, a sealing cover is rotatably connected to the top of the shell, a handle is fixedly connected to the rear side of the sealing cover, a headrest is fixedly connected to the left side of the top of the shell, and a placing plate is fixedly connected to the right side of the shell. The top of the placing plate is fixedly connected with a driving assembly, the left side of the driving assembly is in threaded connection with a moving plate, the top of the moving plate is fixedly connected with a containing shell, and the four corners of the inner wall of the bottom of the containing shell are fixedly connected with containing columns. According to the device, liquid medicine condensed at the bottom of the steam plate is brushed down in the using process of the device, the liquid medicine is flushed and falls into the bottom of the shell, then the liquid medicine can be flushed and heated, then the utilization rate of the liquid medicine by the device is increased, and the liquid medicine condensed on the steam plate can be prevented from blocking the steam holes.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for prompt treatment of cerebral and / or ocular strokes caused by acute dysregulated reduced cerebral blood flow (CBF) and / or ocular blood flow (OBF) by up regulation of trigeminovascular system (TVS), and trigeminal autonomic brain reflexes (TABRs) through stimulation of ophthalmic nerve. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated centrally by intravenous administration of pharmacological dose of ascorbic acid. The site of stimulation of ophthalmic nerve includes but not limited to nasal vestibule, nasal bridge, and forehead and upper eyelid. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for cerebral and ocular strokes. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in cerebral arteries, leptomeningeal collaterals and ophthalmic artery by the release of Vasoactive intestinal peptide (VIP), substance P and CGRP thereof increasing cerebral and / or OBF to the brain and the eye in subject's with acute dysregulated, reduced cerebral and / or OBF. The invention, in some embodiments thereof, is also relates to upregulation of TVS in a manner that is effective to induce acute development of leptomeningeal collateral circulation sufficient to ameliorate the ischemic effect of occluded cerebral artery, enhances successful recanalization, decreases the infarction volume and improves brain functional recovery without hemorrhagic transformation. In some embodiments TVS and ANS are also modulated in a manner that induce an acute increase in choroidal blood flow sufficient to ameliorate the ischemic effect of occluded artery until spontaneous recanalization of the occluded artery is accomplished. The invention is related to targeting the affected side via ipsilateral ONS without inducing intracerebral vascular steal phenomenon. The invention, in some embodiments thereof, is also relates to the methods for improving delivery of oxygen, glucose, anticoagulants, hormones, humoral mediators, growth factors and pharmacological agents to the targeted ischemic tissues of the brain, retina and optic nerve. The methods of the invention, when combined with r-tPA treatment and / or endovascular recanalization increases window time of treatment of stroke, enhance the efficacy of treatment and reduce its side effects. The methods of the invention, in some embodiments thereof, include priming of the brain, retina and / or optic nerve thereof to enhance the efficacy of cell transplantation therapy after exposure to stroke. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment. The cerebral / and or OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.

The invention provides a vehicle-mounted mobile shelter platform for stroke. A detecting instrument, a sound and image collector, a posture adjusting device, a medicine refrigerating box and a display device are arranged in a vehicle body; the system is further provided with a medical cloud platform, and the medical cloud platform is connected with the hospital platform system, the detection instrument, the sound and image collector, the posture adjusting device and the display device through the industrial internet system. The medical cloud platform obtains the data of the detection instrument through an edge heterogeneous data conversion module, performs data protocol and format conversion and edge data cleaning, and sends the data to a structured or unstructured database; intelligent voice recognition and intelligent image recognition are carried out on the edge heterogeneous data conversion module; and the diagnosis and treatment model intelligent body outputs expert system opinions and outputs personnel operation instructions and equipment operation instructions in combination with field decisions or field decisions and remote consultation. Through edge calculation, heterogeneous data conversion and the diagnosis and treatment model agent, the success rate of stroke treatment is greatly improved, and the probability of prognosis sequelae is reduced.

The invention is suitable for the technical field of medical rescue, and provides a dynamic allocation method and system based on a cerebral apoplexy first-aid map, and the method comprises the steps: firstly obtaining the real-time position information of a target patient, then rapidly determining the information of at least one target hospital according to the real-time position information and a preset cerebral apoplexy first-aid map, and obtaining the information of the at least one target hospital; according to the real-time position information and the geographical position information, treatment path information is effectively generated, and finally the treatment path information is sent to a rescue dispatching center in time. According to the method, the stroke treatment hospital most suitable for the specific target patient can be automatically identified, the acute stroke patient in the jurisdiction is ensured to be treated in time in the shortest time by adopting the dynamic planning and optimal scheduling strategy, the emergency scheduling effect is effectively improved, and the success rate of stroke treatment is improved.

The present application belongs to the technical field of medical first aid and resource scheduling, and relates to a stroke emergency green channel pre-starting and resource scheduling method and system. The method comprises: collecting multi-modal diagnosis and treatment data of a stroke patient; calculating a patient condition comprehensive score to determine the patient condition response level; generating a pre-starting instruction corresponding to the intensity; resource time window pre-occupation; synchronously starting the preparation of thrombolysis path tasks and thrombus extraction path tasks for ischemic stroke patients; generating a personalized timing table according to the reverse whole-link task completion time, triggering priority hierarchical upgrade reminders according to the overtime length; recording the whole-process data of diagnosis and treatment according to the preset personalized timing table; and generating a quality control report. Through the innovative design of hierarchical pre-starting, double-path parallel scheduling, whole-process timing control and the like, the present application greatly shortens the stroke treatment time, significantly improves the vascular recanalization rate and the neurological functional prognosis effect of the patient.

Pharmaceutical compositions for treating an ischemic condition in a subject may include inhibitors of protein glycosylation. Methods may include administering to the subject in need thereof an effective amount an inhibitor of protein glycosylation. The administration may be effective to promote endothelial cell proliferation and angiogenesis in the subject. The subject may be in need of induced angiogenesis due to an ischemic condition caused by a stroke. Pharmaceutical compositions for inhibiting protein glycosylation in a cell may include ManN. Methods for inhibiting protein glycosylation in a cell may include administering to a cell an effective amount of ManN.

The invention discloses a rapid cooling device for heat stroke treatment, which comprises a transportation sickbed, a bearing groove is formed in the top end of the transportation sickbed, a connecting shaft is rotatably arranged in the bearing groove, a partition plate is arranged in the bearing groove, and a groove rotatably matched with the connecting shaft is formed in the top end of the partition plate. A trunk supporting plate is fixedly arranged on the peripheral wall of the connecting shaft and located on one side of the partition plate, a head supporting plate is arranged on the peripheral wall of the connecting shaft and located on the other side of the partition plate, and a neck supporting table is arranged at the upper end of the head supporting plate. The invention relates to the technical field of heat stroke cooling. According to the rapid cooling device for heat stroke treatment, the trunk and the head of a patient are made to incline by two sections through two sets of angle adjusting equipment, the head of the patient can have a large inclination angle, when the patient vomits, the effect that vomitus can be discharged conveniently can be achieved, and then the patient can be effectively prevented from choking the trachea; and dyspnea is caused.

The application belongs to the technical field of heat stroke treatment, and specifically discloses application of DNAzyme in preparation of a medicine for treating heat stroke, wherein the DNAzyme is a DNAzyme for targeted regulation of ZBP1 protein expression. The application also discloses a medicine for preventing and treating heat stroke. The application has important value for fundamentally conquering the prevention and treatment method of heat stroke. The application fully verifies the remarkable efficacy of DNAzyme_SEQ_1 in the prevention and treatment of heat stroke through systematic experiments. The DNAzyme_SEQ_1 delivered by a TPNs carrier presents obvious liver and lung targeting in the mouse body, and the fluorescence intensity is obviously higher than that of other organs, thereby ensuring that the medicine precisely acts on the key damage sites of heat stroke.

The invention relates to the field of medicine, in particular to a nitrite donor-albumin coupling medicine and a preparation method and application thereof. According to the nitrite donor-albumin coupling drug disclosed by the invention, an intelligent drug delivery system with a pH response characteristic is constructed by covalently coupling a nitrite donor compound or a derivative thereof and albumin, so that the bottleneck problems of short half-life period (lt: 1h), non-specific release, poor blood-brain barrier penetrability and the like of a traditional nitrite drug are effectively solved. The coupling medicine can significantly improve cerebral ischemia reperfusion injury through vasodilation regulation and oxidation resistance, and the infarct area is significantly reduced (about 2 times). The breakthrough provides a brand new normal form for developing cerebral apoplexy treatment medicines with targeting accuracy and multi-dimensional treatment, and has important clinical transformation value.

The invention belongs to the technical field of biological medicines, and particularly relates to application of rhubarb and ackermann bacteria in preparation of an anti-cerebral apoplexy medicine. It is found for the first time that the rhubarb aqueous extract (DH) can promote growth of ackermania muciniphila (AKK) and increase production of citrulline (Cit) metabolites, and in-vivo and in-vitro experiments prove that the combination of DH and AKK can significantly relieve cerebral ischemia-reperfusion injury, improve neurological dysfunction and promote brain tissue repair, and can be used for treating cerebral ischemia-reperfusion injury, cerebral ischemia-reperfusion injury, cerebral ischemia-reperfusion injury, cerebral ischemia-reperfusion injury and cerebral ischemia-reperfusion injury. The research result not only deepens the understanding of the pathological mechanism of the cerebral apoplexy from the molecular level, but also provides a solid theoretical basis and experimental support for developing a targeted treatment strategy based on DH combined with AKK, is expected to break through the bottleneck of current cerebral apoplexy treatment, and opens up a new intervention way for the optimization of a clinical treatment scheme.

The invention belongs to the field of stroke treatment, and provides an application of a metabolite Lacc-Phe or a synthetase CNDP2 thereof as an acute ischemic stroke treatment target, and a reagent for knocking out or knocking down the expression level of CNDP2 or an inhibitor of CNDP2 can be used for treating acute ischemic stroke or cerebral ischemia reperfusion injury. According to the application, an endogenous metabolite N-lactoyl phenylalanine (Lacc-Phe) and a synthetase CNDP2 thereof are found to be obviously increased after cerebral ischemia reperfusion injury, and the endogenous metabolite N-lactoyl phenylalanine (Lacc-Phe) and the synthetase CNDP2 thereof have relatively strong correlation with a reported cerebral arterial thrombosis marker; in addition, the knockout of the CNDP2 and the inhibitor bestatin (bestatin) of the CNDP2 can protect the cerebral ischemia reperfusion injury, and the overexpression of the CNDP2 and the exogenous administration of the Lacc-Phe can aggravate the cerebral ischemia reperfusion injury, so that the CNDP2 / Lacc-Phe axis can be used as a diagnosis, treatment and prognosis target of the cerebral arterial thrombosis disease.

Described herein are compositions (e.g., an inhibitory nucleic acid molecule) for reducing expression of small EDRK-rich factor 2 (SERF2) and methods thereof for (i) treating cardiovascular disease (e.g., PAD, CAD, heart failure, cardiomyopathy, or stroke) in a subject; (ii) treating or reducing the likelihood of CTLI in a subject; (iii) alleviating chronic ischemic rest pain in a subject having CTLI; and / or (iv) promoting angiogenesis in a subject (e.g., a subject having or at risk of developing a cardiovascular disease). The inhibitory nucleic acid molecule may be a small interfering RNA (siRNA), a double-stranded RNA (dsRNA), an anti-sense oligonucleotide (ASO), a microRNA (miRNA), a short hairpin RNA (shRNA), or a gapmeR described herein, or a composition (e.g., pharmaceutical composition) thereof.

The rapid cooling device comprises a neck guard and a cooling assembly, the cooling assembly comprises a moving block slidably clamped on the outer side of the neck guard, a guide frame is connected to the top end of the moving block, a pair of guide grooves are formed in the inner side of the guide frame, and a pair of arc-shaped plates are symmetrically arranged at the top end of the neck guard; the inner sides of the two arc-shaped plates and the guide frame are located on the same spherical surface, a plurality of sprayers are arranged on the inner side of the guide frame, all the sprayers are connected to a control pump through pipelines, the control pump is arranged on the outer side of the moving block, and a uniform assembly is arranged on the inner side of the guide frame; the cooling assembly and the uniformizing assembly can jointly cool the head of a patient, a rolling wheel can roll along the outer side of the head of the patient in the sliding process of a guide frame, low-temperature alcohol can be more evenly smeared on a pressing film on the outer side of the head of the patient, the cooling effect of the head of the patient is guaranteed, and meanwhile the skin of the head of the patient is prevented from being frostbitten.

The invention relates to a cerebral apoplexy treatment time window prolonging agent, application of the cerebral apoplexy treatment time window prolonging agent and a cerebral apoplexy thrombolysis kit, and the cerebral apoplexy treatment time window prolonging agent comprises a protein PAI-1 targeting inhibitor, the compound is used for being specifically combined with a plasminogen activator inhibitor PAI-1 released by activated platelets in a cerebral apoplexy thrombus area so as to inhibit the fibrinolytic inhibitory activity of the PAI-1. The invention has the beneficial effects that endogenous fibrinolysis is activated in a safe and effective way, the sharp contradiction between timeliness and safety in the prior art is directly solved, and the medicine is expected to be used as a safe early intervention medicine and provides new treatment possibility for a large number of patients who miss initial treatment opportunities. By means of the exquisite unlocking mechanism, the cerebral apoplexy treatment time window is delayed to 6 h, and precious time is gained for cerebral apoplexy treatment subsequently.

The present invention relates to the use of antithrombin in the treatment of stroke.

The present invention relates to the technical field of medicines and disclosed are a neuroprotective polypeptide compound and an application thereof. The neuroprotective polypeptide compound comprises a polypeptide having the following chemical formula and a salt thereof: (M)m-(Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu)-(N)n; m and n are integers from 0 to 3, but m and n are not zero at the same time; M is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His, and N is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His. An intravenous dosage of only 3 mg / kg can unexpectedly achieve a significant therapeutic effect and achieve the same effect as NA1. The polypeptide compound can be used in combination with a hemolytic drug to provide a new possibility for the treatment of stroke.